Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
NCT02974647Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2016
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in T-cell lymphoma, natural killer cell lymphoma (NKCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2016; status: recruiting.
02
Drugs
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT02974647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974647.